GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

Transcription

1 GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT 1) TOPIC OF THE EVENT MALIGNANT PLEURAL DISEASE 2) SUGGESTED TITLE : Approach to Pleural Cancer: State-of-the-Art 3) TYPE OF EVENT Course Native Language English 4) YEAR: ) SUGGESTED DATE May ) VENUE: Athens University Central Building Lecture Theatre (capacity 250) 7) ORGANISERS Ioannis Kalomenidis MD University of Athens, Greece Jan P van Meerbeeck, MD, PhD, University hospital Ghent (Belgium) 8) SCIENTIFIC COMMITTEE: Y C Gary Lee MBChB PhD FRACP FCCP Oxford University, UK Paul De Vuyst, MD, PhD (Hôpital Erasme, Brussels, Belgium) Paul Baas, MD, PhD (Netherlands Cancer Institute, Amsterdam, NL) 8) WHY IS THIS EVENT NEEDED? Clinical Significance: Malignant pleural effusions complicate most cancers: 95% of patient with mesothelioma, 30% of those with breast and 25% of those with lung cancer develop a malignant effusion. Malignant involvement of the pleura often results in disabling dyspnea from effusions, pain and drastically impairs quality of life. Despite its frequent occurrence, management of malignant effusions are often handled late and sub-optimally. Significant and exciting advances have been made recently in the field of the treatment of malignant pleural diseases, many of which impacts directly on the care of patients A first ESO course on malignant mesothelioma was held in Brussels in 2007 and was considered successful. By expanding the programme to other pleural malignancies, we are confident that the proposed course will raise the awareness and management standard for patients with malignant pleural diseases. Speakers: The chairs of the meeting have extensive experience in organizing national and international symposiums on pleural diseases, including pleural symposiums at annual conferences of the American Thoracic Society, American College of Chest Physicians, American Society of Clinical oncology, European organisation for Research and Treatment of Cancer, the International Association for the Study of Lung Cancer and the International Mesothelioma Interest Group. The organizers have chaired pleural disease sessions in most major respiratory and oncological conferences. This proposed course presents a unique opportunity to bring together leading clinical pleural researchers with strong track records and international speaking experiences to provide a concise update on the latest advances in the approach to pleural malignancies, from new etiologic concepts

2 to clinical evidence that changes patient care, including new international guidelines on pleural disease management. Objectives: The audience will be equipped with up-to-date understanding of concepts of pathogenesis as well as practical guides to management of pleural malginancies, allowing participants to gain insight and confidence in the care of patients with pleural cancers. This program will cover the - latest advances in the understanding of the pathophysiology of malignant pleural disease which has led to novel translational approaches already in clinical or pre-clinical trials. - presentations of metastatic pleural diseases associated with lung, breast, hematological malignancies as well as malignant pleural mesothelioma. - state-of-the-art diagnostic tools for pleural malignancies, including advanced radiological modalities (eg PET), thoracoscopy (medical and surgical) etc. - pros/cons and current controversies for conventional treatment for malignant pleural effusions, especially pleurodesis. - new treatment concepts and practice for malignant effusions, eg indwelling tunnelled pleural catheters. - role of surgery, chemotherapy and radiotherapy in pleural malignancies. - palliative and psychological aspects of management of patients with malignant pleural diseases 9) WHAT IS THE TARGET AUDIENCE? The management of patients with malignant pleural diseases involve an integral approach of medical specialists of various disciplines as well as the allied health professionals. Hence this course has strong appeal to a broad range of audience. Target Audience: Practicing pulmonologists, medical and radiation oncologists, palliative care physicians, internists, radiologists, and trainees in these specialities, related health care professionals especially cancer nurses.

3 10) DETAILS OF PROGRAMME Day 1: 09:00-09:30: Registration 09:30-09:45: Welcome and Introduction: Significance of malignant pleural diseases Y C Gary Lee Oxford, UK - Consultant chest physician and senior lecturer, Oxford University - Author of Textbook of Pleural Diseases, member of British Thoracic Society working group on pleural disease guidelines, regular speaker on pleural disease symposiums 09:45-10:05: Epidemiology of mesothelioma in Europe and the Eastern Mediterranean Region Raba Gaafar, Cairo, Egypt - Medical Oncologist, Director Dpt of Medical Oncology Marmara University - Involved in the care of mesothelioma patients in Turkey 10:05-10:25: Legislation, compensation and claim: an European overview Paul Baas Amsterdam, the Netherlands - Chest physician at the netherlands cancer institute - Chairman of the EORTC-Lung Cancer Group - Leading expert on mesothelioma diagnosis and treatment 10:25-11:00: Essential Anatomy and Physiology of the Pleural Space for Clinicians Marc Noppen Brussels, Belgium - Chest physician and CEO, AZ Hospital, Brussels - Leading authority on interventional thoracoscopy and experienced speaker to demonstrate pleural anatomy as seen using thoracoscopy 11:00-11:20: Coffee Break 11:20-11:40: From fiber to cancer: pathogenesis of asbestos related pleuro-pulmonary disease Paul De Vuyst Brussels, BE - Chest physician and Head of the department of Respiratory Medicine, Hôpital Erasme, Université Libre de Bruxelles - Expert on asbestos related pulmonary diseases 11:40-12:00: Essential Immunobiology of Malignant Pleural Effusions for Clinicians George Stathopoulos Athens, Greece - Chest physician, Consultant, Department of Critical Care and Pulmonary Services, Athens University Medical School, Evangelismos Hospital, Athens - Active research leader on molecular mechanisms of malignant effusion formation; recently described novel experimental model of malignant effusion that significantly enhanced research in the field 12:00-12:35: Clinical Presentations of Malignant Pleural Diseases Nick A Maskell Bristol, UK - Chest Physician and Senior Lecturer, University of Bristol - Lead coordinator of the British Thoracic Society Guidelines for Pleural Diseases; first author to high profile clinical pleural trials in New Engl J Med and Lancet; Editor of the Oxford Desk Reference for Respiratory Diseases

4 12:35-12:55 Diagnosis of Malignant Pleural Diseases: Overview Robert Davies Oxford, UK - as above 12:55-14:00: Lunch 14:00 14:35 Advances in Diagnosis of Malignant Pleural Diseases: Radiology Fergus V Gleeson Oxford, UK - Radiologist and Senior Lecturer, Oxford University - World s leading radiologist on pleural diseases; Editor of British Journal of Radiology; Member of the National Institute of Clinical Excellence (NICE), UK; regular speaker on pleural radiology in international respiratory and radiology conferences 14:35-15:05 Advances in Diagnosis of Malignant Pleural Diseases: Thoracoscopy Marc Noppen Brussels, Belgium - as above - Experienced in training and aiding clinicians in developing medical thoracoscopy services 15:05 15:35 Advances in Diagnosis of Malignant Pleural Diseases: Pathology Keith Kerr Aberdeen, UK - Head of the deparment of Pathology, University of Aberdeen - EORTC-LCG pathology chair - Leading pulmonary pathologist - 15:35-15:55 Advances in Diagnosis of Malignant Pleural Diseases: Tumor Markers Arnaud Scherpereel Lille, France - Chest Physician and research group leader, INSERM - Leader of Société de Pneumologie de Langue Française on malignant pleural mesothelioma; active publication records on new tumor markers for malignant pleural effusions, especially soluble mesothelin for mesothelioma 15:55-16:20 Staging and work-up of mesothelioma: Jan P van Meerbeeck Ghent, Belgium - Chest physician, professor of Thoracic Oncology, University of Ghent - Past chairman of the EORTC-LCG - Leading expert on mesothelioma diagnosis and treatment

5 Day 2: 9:30-9:45 Management of Malignant Pleural Diseases: Overview Ioannis Kalomenidis Athens, Greece - Chest Physician and Lecturer, 2 nd Department of Pulmonary Medicine, Athens University Medical School, Atticon Hospital - Leader of laboratory research group focusing on malignant pleural effusions; active research interests in cytokines governing vascular permeability leading to accumulation of pleural effusions 9:45-10:20 Advances in Management of Malignant Pleural Effusions: Pleurodesis Y C Gary Lee Oxford, UK - as above - this talk will cover the recent controversies on talc as pleurodesing agent (including recent alert by the Medicines and Health Regulatory Agency on its potential harmful effects), International survey on pleurodesis practice etc. 10:20-10:40 Advances in Management of Malignant Pleural Effusions: Indwelling Tunneled Pleural Catheters and other drainage techniques Robert J O Davies Oxford, UK - Reader and Consultant Chest Physician, University of Oxford - Leader investigator to many high profile pleural disease clinical trials, including the ongoing British Lung Foundation randomized controlled trial using indwelling catheters as first line management of malignant effusions. 10:40-11:00 Surgical procedures in pleural malignancies Paul Van Schil, Antwerp, Belgium - Head Dpt of Thoracic Surgery University Hospital Antwerp, BE - Surgical Chair EORTC-LCG - Studycoordinator of a multicenter phase 2 multimodality trial in mesothelioma 11:00-11:20: Coffee break 11:20-11:55 Chemotherapy of pleural malignancies Mary O Brien Sutton, UK - Medical oncologist Royal Marsden Hospital, London - Chemotherapy chair and chair elect EORTC LCG - Leading expert on chemotherapy in mesothelioma 11:55-12:25 Radiotherapy in malignant pleural diseases Suresh Senan Amsterdam, NL - Radiation oncologist Free University Medical Center, - Radiation Therapy Chair EORTC LCG 12:25 12:50 Biological therapy of mesothelioma: Paul Baas, Amsterdam, the Netherlands

6 As above 12:55-14:00: Lunch 14:00-14:45: Multimodality treatment of mesothelioma: the European experience Mary O Brien Sutton, UK Paul Van Schil, Antwerp, Belgium Suresh Senan Amsterdam, NL As above 14:45 15:05 Symptomatic treatment of malignant pleural mesothelioma Helen Clayson, Barrow-in-Furness UK - Director of St Mary s Hospice, Barrow-in-Furness - Expert on palliative care 15:05-15: 25: European guidelines in mesothelioma diagnosis and treatment: Arnauld Scherpereel Lille, France As above : Concluding remarks and adjourn Jan P van Meerbeeck Ghent, Belgium As above